Key Developments: Achillion Pharmaceuticals Inc (ACHN.O)

ACHN.O on Nasdaq

7.79USD
2:12pm EDT
Price Change (% chg)

$0.76 (+10.81%)
Prev Close
$7.03
Open
$6.98
Day's High
$7.89
Day's Low
$6.97
Volume
4,909,397
Avg. Vol
6,213,025
52-wk High
$8.61
52-wk Low
$2.26

Search Stocks

Latest Key Developments (Source: Significant Developments)

Achillion Pharmaceuticals Inc Announces Pricing of Public Offering of Common Stock
Thursday, 21 Feb 2013 08:00pm EST 

Achillion Pharmaceuticals Inc announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock at a price to the public of $8.40 per share. The net proceeds to Achillion from the sale of the shares, after deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $118.5 million. The offering is expected to close on February 27, 2013. Citigroup and Leerink Swann LLC are acting as joint book-running managers, and JMP Securities LLC, Piper Jaffray & Co. and Wells Fargo Securities, LLC are acting as co-managers for the offering. Achillion has granted the underwriters a 30-day option to purchase up to an additional 2,250,000 shares of its common stock. The expected net proceeds to Achillion referenced above do not include any net proceeds that Achillion would receive if the underwriters exercise such option.  Full Article

Achillion Pharmaceuticals Inc Issues FY 2013 EPS Guidance In Line With Analysts' Estimates
Wednesday, 20 Feb 2013 04:08pm EST 

Achillion Pharmaceuticals Inc announced that for fiscal 2013 the net loss per share (EPS) is anticipated to approximate $0.75 per share for fiscal 2013. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report EPS of ($0.75) for fiscal 2013.  Full Article

Achillion Pharmaceuticals Inc Announces Proposed Public Offering Of Common Stock
Wednesday, 20 Feb 2013 04:07pm EST 

Achillion Pharmaceuticals Inc announced that it has commenced an underwritten public offering of $125 million of its common stock. In connection with this offering, Achillion plans to grant the underwriters a 30-day option to purchase additional shares of its common stock. Citigroup and Leerink Swann LLC are acting as joint book-running managers for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.  Full Article

Achillion Pharmaceuticals Inc Reaffirms FY 2012 EPS Guidance-Conference Call
Wednesday, 8 Aug 2012 02:00pm EDT 

Achillion Pharmaceuticals, Inc. announced that for fiscal 2012, it expects net loss per share to range from $0.65 to $0.70 per share (EPS). According to I/B/E/S Estimates, analysts on an average were expecting the Company to report net loss per share of $(0.65) for fiscal 2012.  Full Article

Achillion Pharmaceuticals Inc Announces Positive SVR4 Results From Phase 2 Study Of Sovaprevir (Formerly ACH-1625) and Advancement Of ACH-3102
Tuesday, 7 Aug 2012 04:06pm EDT 

Achillion Pharmaceuticals Inc announced sustained viral response (SVR4) results of 85 to 100% from an ongoing multi-dose Phase 2 trial evaluating 12 weeks of dosing with sovaprevir (formerly ACH-1625), a once-daily protease inhibitor, in combination with pegylated interferon plus ribavirin (P/R) followed by an additional 12 weeks of P/R. In addition, the Company announced that ACH-3102, a second-generation pan-genotypic NS5A inhibitor, has been safe and well tolerated by healthy volunteers in both single and 14-day multiple ascending dose groups. Further, enrollment of patients in a Phase 1 proof-of-concept clinical trial to evaluate the safety and efficacy of ACH-3102 in patients with genotype 1 HCV has been initiated.  Full Article

US STOCKS-Wall St ends near flat; Dow hits record for 4th day

* Dow up 0.02 pct, S&P 500 down 0.02 pct, Nasdaq up 0.04 pct (Updates to close)

Search Stocks